SG11201808367UA - Azelaic acid esters in the treatment of insulin resistance - Google Patents
Azelaic acid esters in the treatment of insulin resistanceInfo
- Publication number
- SG11201808367UA SG11201808367UA SG11201808367UA SG11201808367UA SG11201808367UA SG 11201808367U A SG11201808367U A SG 11201808367UA SG 11201808367U A SG11201808367U A SG 11201808367UA SG 11201808367U A SG11201808367U A SG 11201808367UA SG 11201808367U A SG11201808367U A SG 11201808367UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- insulin resistance
- hours
- texas
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 111111111111111111110111011111011111111111100111111111011110111111 Organization International Bureau (10) International Publication Number 0 (43) International Publication Date .....0\"\" WO 2017/184767 Al 26 October 2017 (26.10.2017) WIPO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: (74) Agent: BEHAR, Victor; c/o Pillsbury Winthrop Shaw A61K 31/23 (2006.01) A01N 37/06 (2006.01) Pittman LLP, P.O. BOX 10500, McLean, Virginia 22101 A01N 37/02 (2006.01) (US). International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/028417 kind of national protection available): AE, AG, AL, AM, International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 19 April 2017 (19.04.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/325,381 20 April 2016 (20.04.2016) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: NEW FRONTIER LABS, LLC [US/US]; Suite 800, 9901 IH10 West, San Antonio, Texas 78230 (84) Designated States (unless otherwise indicated, for every (US). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Inventors: STREEPER, Robert T.; 7738 Apple Green UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Road, San Antonio, Texas 78240 (US). IZBICKA, Elzbi-TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, eta; 7738 Apple Green Road, San Antonio, Texas 78240 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) = position Title: AZELAIC ACID ESTERS IN THE TREATMENT OF INSULIN RESISTANCE 160 = = Blood glucose vs. time = (control) ....1111..• GTT + ET 150 = — —0— GTT+ET +DEA 140 -ca uo 130 E i d , \ a) 120 '8 0 i f = = = — = = 0 110 CS) 0 0 \"0 0 100 % 0 0 90 t ° 80 .. ........._ . . .. 70 r 0 hours 1 hours 2 hours 4 hours Figure 4 : A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical cam- that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day. IN IN = - - — = — 1-1 IN ii- cc ,-1 -- -- r , (57) - diethyl ei C [Continued on next page] WO 2017/184767 Al MIDEDIMOMMIDIRMEMOMENHOMINHINVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325381P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028417 WO2017184767A1 (en) | 2016-04-20 | 2017-04-19 | Azelaic acid esters in the treatment of insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808367UA true SG11201808367UA (en) | 2018-10-30 |
Family
ID=60088670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808367UA SG11201808367UA (en) | 2016-04-20 | 2017-04-19 | Azelaic acid esters in the treatment of insulin resistance |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10251857B2 (en) |
| EP (2) | EP3445354B8 (en) |
| JP (2) | JP7072762B2 (en) |
| KR (1) | KR102233912B1 (en) |
| CN (1) | CN109195597B (en) |
| AU (2) | AU2017253088B2 (en) |
| CA (1) | CA3021516C (en) |
| DK (1) | DK3445354T3 (en) |
| ES (1) | ES2925775T3 (en) |
| HR (1) | HRP20220988T1 (en) |
| HU (1) | HUE059844T2 (en) |
| LT (1) | LT3445354T (en) |
| NZ (1) | NZ746669A (en) |
| PL (1) | PL3445354T3 (en) |
| PT (1) | PT3445354T (en) |
| RS (1) | RS63558B1 (en) |
| SG (1) | SG11201808367UA (en) |
| SI (1) | SI3445354T1 (en) |
| WO (1) | WO2017184767A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3445354T1 (en) * | 2016-04-20 | 2022-10-28 | New Frontier Labs, Llc | Azelaic acid esters in the treatment of insulin resistance |
| IL295663A (en) * | 2020-02-19 | 2022-10-01 | New Frontier Labs Llc | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2426683A1 (en) * | 1974-06-01 | 1975-12-18 | Boehringer Mannheim Gmbh | BIGUANID AND METHOD FOR MANUFACTURING THEREOF |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO2001012786A1 (en) * | 1999-08-16 | 2001-02-22 | Human Genome Sciences, Inc. | Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| ATE454895T1 (en) * | 2001-08-13 | 2010-01-15 | Univ Yale | METHOD FOR INDUCING A SELECTIVELY SUPPRESSED IMMUNE RESPONSE |
| US7149574B2 (en) * | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
| US20080051373A1 (en) * | 2003-07-31 | 2008-02-28 | The Board Of Regents Of The University Of Texas System | Parenteral preparations of GI-safer phospholipid-associated anti-inflammatories and methods of preparation and use |
| WO2006074379A2 (en) | 2005-01-07 | 2006-07-13 | Azaya Therapeutics, Inc. | Methods and compositions involving esters of azelaic acid and other dicarboxylic acids |
| US8440217B1 (en) * | 2005-06-15 | 2013-05-14 | Mawaheb M. EL-Naggar | Method and system with contact lens product for treating and preventing adverse eye conditions |
| EP1909766B1 (en) * | 2005-07-28 | 2016-03-16 | Shire LLC | PHARMACEUTICAL FORMULATIONS/COMPOSITIONs OF GUANFACINE SUITABLE FOR SINGLE DAILY DOSE |
| US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US8093017B2 (en) * | 2005-12-07 | 2012-01-10 | Siemens Heathcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics |
| ES2390620T3 (en) * | 2008-03-10 | 2012-11-14 | Nestec S.A. | Medium chain dicarboxylic acids and their derivatives and metabolic disorders |
| US20090326069A1 (en) * | 2008-06-30 | 2009-12-31 | Bltn, Llc | Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers |
| US20120251525A1 (en) * | 2009-06-30 | 2012-10-04 | Streeper Robert T | Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules |
| US9023887B2 (en) * | 2011-04-15 | 2015-05-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Lipase inhibitors for the treatment of pancreatitis and organ failure |
| KR101593539B1 (en) * | 2015-07-03 | 2016-02-15 | 고려대학교 산학협력단 | Composition of Azelaic Acid Having Adipose Triglyceride Hydrolysis effect |
| SI3445354T1 (en) * | 2016-04-20 | 2022-10-28 | New Frontier Labs, Llc | Azelaic acid esters in the treatment of insulin resistance |
-
2017
- 2017-04-19 SI SI201731210T patent/SI3445354T1/en unknown
- 2017-04-19 ES ES17786579T patent/ES2925775T3/en active Active
- 2017-04-19 JP JP2018552655A patent/JP7072762B2/en active Active
- 2017-04-19 EP EP17786579.7A patent/EP3445354B8/en active Active
- 2017-04-19 PL PL17786579.7T patent/PL3445354T3/en unknown
- 2017-04-19 US US15/491,937 patent/US10251857B2/en active Active
- 2017-04-19 NZ NZ746669A patent/NZ746669A/en unknown
- 2017-04-19 HU HUE17786579A patent/HUE059844T2/en unknown
- 2017-04-19 CA CA3021516A patent/CA3021516C/en active Active
- 2017-04-19 PT PT177865797T patent/PT3445354T/en unknown
- 2017-04-19 HR HRP20220988TT patent/HRP20220988T1/en unknown
- 2017-04-19 DK DK17786579.7T patent/DK3445354T3/en active
- 2017-04-19 SG SG11201808367UA patent/SG11201808367UA/en unknown
- 2017-04-19 RS RS20220773A patent/RS63558B1/en unknown
- 2017-04-19 EP EP22175016.9A patent/EP4085907A1/en active Pending
- 2017-04-19 CN CN201780024922.8A patent/CN109195597B/en active Active
- 2017-04-19 LT LTEPPCT/US2017/028417T patent/LT3445354T/en unknown
- 2017-04-19 WO PCT/US2017/028417 patent/WO2017184767A1/en active Application Filing
- 2017-04-19 AU AU2017253088A patent/AU2017253088B2/en active Active
- 2017-04-19 KR KR1020187033326A patent/KR102233912B1/en active IP Right Grant
-
2019
- 2019-02-04 US US16/267,338 patent/US11026912B2/en active Active
-
2021
- 2021-03-01 JP JP2021031730A patent/JP7088460B2/en active Active
- 2021-05-12 US US17/318,586 patent/US20210260014A1/en active Pending
-
2022
- 2022-06-02 AU AU2022203809A patent/AU2022203809B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201408261UA (en) | Syringe | |
| SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201805942UA (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
| SG11201808650QA (en) | Methods of treating ocular conditions | |
| SG11201408292YA (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
| SG11201806127XA (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201805092WA (en) | Cortistatin analogs and uses thereof | |
| SG11201808367UA (en) | Azelaic acid esters in the treatment of insulin resistance |